NLRP3 and escherichia coli infection: Given the role of NLRP3 in E. coli infection, we screened drugs targeting NLRP3 using a drug library and identified candidates that effectively bind to NLRP3 (e.g., digitoxin, a cardiotonic drug), providing a list of potential drugs for treating E. coli-induced gut inflammation in the future.